Azathioprine (AZA) has long been used in dermatology in treating autoimmune bullous dermatoses and generalized eczematous disorders as well as some photodermatoses. Its metabolic process inside human body and its side effects relies on genetic polymorphism of some enzymes such as thiopurine s-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase gene (ITPA). This study aims to analyze the relative contribution of TMPT and ITPA mutations to the development of toxicity induced by AZA treatment and to detect the correlation of the genetic polymorphism.

NCT00525473

Conditions

1. Azathioprine
2. Thiopurine Methyltransferase
3. Inosine Triphosphate Pyrophosphatase
4. Genetic Polymorphism

Interventions

1. Drug: Azathioprine

current treatment to nausea/vomiting adverse effects induced by azathioprine combined with pre-therapeutic genetic screening, especially polymorphism ITPA C94A, may reduce the possibility for developing hematopoietic toxicity and/or hepatotoxicity.. Inclusion Criteria: - Patients who have used or are using azathioprine in treating skin diseases will be asked about treatment effects and adverse events. --- C94A ---

The aim of our study was to determine the relative contribution of, TMPT(A719G) and ITPA(C94A) mutations to the development of toxicity induced by AZA treatment in dermatology patients and to detect the correlation of these two genetic polymorphism. --- A719G --- --- C94A ---